Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 15/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30326251 | 0.84 | AAK1 (0.50) | AAK1 | |
| SCHEMBL15241159 | 0.84 | AAK1 (0.50) | AAK1 | |
| SCHEMBL55502 | 0.83 | TDP1 (0.46) | APLNRAAK1TDP1CA1CA2 | |
| SCHEMBL22633280 | 0.78 | — | — | |
| SCHEMBL19997953 | 0.77 | CA1 (0.41) | APLNRAAK1TDP1CA1CA2 | |
| SCHEMBL19940938 | 0.77 | CA1 (0.41) | APLNRAAK1TDP1CA1CA2 | |
| SCHEMBL22380444 | 0.75 | APLNR (0.44) | APLNRAAK1TDP1CA1CA2 | |
| SCHEMBL13700790 | 0.75 | TDP1 (0.56) | APLNRAAK1TDP1CA1CA2 | |
| SCHEMBL18138208 | 0.75 | TDP1 (0.40) | APLNRAAK1TDP1CA1CA2 | |
| SCHEMBL22644354 | 0.75 | APLNR (0.41) | APLNRAAK1TDP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11491148-B2 | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2022-11-08 | — | — | US | disclosed |
| EP-3966205-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-03-16 | — | — | EP | disclosed |
| US-20200352925-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-12 | — | — | US | disclosed |
| WO-2020225230-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352925-A1 | AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HBV INFECTION OR HBV-INDUCED DISEASES | HDGF, FABP1, NR1H4 | APLNR 625/4885AAK1 1721/4885TDP1 4673/4885 |
| US-11491148-B2 | Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases | HDGF, HAVCR2, FABP1 | APLNR 726/4885AAK1 2777/4885TDP1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.